Infections within 100 days of idecabtagene vicleucel and impact on survival for relapsed/refractory multiple myeloma: A CIBMTR Analysis
{{output}}
Background: Infections are common after chimeric antigen receptor (CAR) T-cell therapy and contribute to morbidity and mortality. While well characterized with CD19 CAR T-cells, data related to infections with B-cell maturation a... ...
